Skip to main content

NASDAQ:GMAB - Genmab A/S Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $41.57
  • Forecasted Upside: 11.48 %
  • Number of Analysts: 15
  • Breakdown:
  • 2 Sell Ratings
  • 4 Hold Ratings
  • 9 Buy Ratings
  • 0 Strong Buy Ratings
$37.29
▼ -0.11 (-0.29%)
1 month | 3 months | 12 months
Get New Genmab A/S Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GMAB and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GMAB

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$41.57
▲ +11.48% Upside Potential
This price target is based on 15 analysts offering 12 month price targets for Genmab A/S in the last 3 months. The average price target is $41.57, with a high forecast of $49.00 and a low forecast of $36.00. The average price target represents a 11.48% upside from the last price of $37.29.

Hold

The current consensus among 15 investment analysts is to hold stock in Genmab A/S. This rating has held steady since September 2020, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
11/16/2019
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/14/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/14/2020
  • 0 strong buy ratings
  • 10 buy ratings
  • 2 hold ratings
  • 2 sell ratings
8/12/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
11/10/2020
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
2/8/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 4 hold ratings
  • 2 sell ratings
4/9/2021
  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 2 sell ratings
5/9/2021

Latest Recommendations

  • 0 strong buy ratings
  • 9 buy ratings
  • 4 hold ratings
  • 2 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/26/2021Morgan StanleyLower Price TargetEqual Weight$41.00 ➝ $37.00N/A
i
4/20/2021Deutsche Bank AktiengesellschaftInitiated CoverageBuyLow
i
4/19/2021Morgan StanleyLower Price TargetEqual Weight$41.00 ➝ $37.00Low
i
3/15/2021DNB MarketsUpgradeSell ➝ BuyLow
i
3/9/2021JPMorgan Chase & Co.Reiterated RatingOverweightLow
i
3/9/2021UBS GroupReiterated RatingBuyLow
i
3/3/2021SVB LeerinkLower Price TargetMarket Perform$38.00 ➝ $36.00Medium
i
Rating by J. Chang at SVB Leerink LLC
2/25/2021TruistBoost Price Target$42.00 ➝ $47.00Low
i
2/25/2021SVB LeerinkLower Price TargetMarket Perform$38.00 ➝ $36.00High
i
Rating by J. Chang at SVB Leerink LLC
2/24/2021BarclaysReiterated RatingOverweightHigh
i
2/24/2021DanskeUpgradeHold ➝ BuyMedium
i
2/11/2021HC WainwrightReiterated RatingBuyLow
i
1/26/2021SVB LeerinkBoost Price TargetMarket Perform$34.00 ➝ $38.00Medium
i
Rating by J. Chang at SVB Leerink LLC
1/25/2021DNB MarketsDowngradeHold ➝ SellMedium
i
1/19/2021Morgan StanleyDowngradeOverweight ➝ Equal WeightLow
i
1/15/2021HC WainwrightBoost Price TargetBuy$44.00 ➝ $49.00High
i
1/4/2021Royal Bank of CanadaBoost Price TargetPositive ➝ Outperform$40.00 ➝ $46.00N/A
i
12/16/2020Morgan StanleyBoost Price TargetOverweight$37.00 ➝ $41.00Low
i
12/9/2020SVB LeerinkLower Price TargetMarket Perform$36.00 ➝ $34.00Medium
i
Rating by J. Chang at SVB Leerink LLC
11/25/2020HC WainwrightLower Price TargetBuy$45.00 ➝ $44.00Low
i
Rating by Ram Selvaraju at HC Wainwright
11/16/2020UBS GroupReiterated RatingBuyLow
i
11/5/2020Morgan StanleyBoost Price TargetOverweight$35.00 ➝ $37.00Low
i
11/5/2020HC WainwrightBoost Price TargetBuy$42.00 ➝ $45.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
10/27/2020The Goldman Sachs GroupBoost Price TargetNeutral$37.00High
i
10/13/2020Morgan StanleyBoost Price TargetOverweight$32.00 ➝ $35.00Low
i
9/23/2020HC WainwrightBoost Price TargetBuy$41.00 ➝ $42.00High
i
Rating by Ram Selvaraju at HC Wainwright
9/23/2020Bryan, Garnier & CoDowngradeNeutral ➝ SellHigh
i
9/8/2020SVB LeerinkInitiated CoverageMarket Perform$35.00Low
i
Rating by J. Chang at SVB Leerink LLC
8/24/2020TruistBoost Price Target$39.00 ➝ $41.00Low
i
8/21/2020HC WainwrightBoost Price TargetBuy$40.00 ➝ $41.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
8/13/2020Royal Bank of CanadaBoost Price TargetOutperform$35.00 ➝ $38.00Low
i
8/13/2020Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $32.00High
i
8/13/2020HC WainwrightReiterated RatingBuyHigh
i
Rating by Ram Selvaraju at HC Wainwright
7/17/2020HC WainwrightReiterated RatingBuy$40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
7/2/2020Societe GeneraleInitiated CoverageSellLow
i
6/30/2020HC WainwrightReiterated RatingBuy$40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
6/25/2020Credit Suisse GroupDowngradeOutperform ➝ NeutralLow
i
6/19/2020Royal Bank of CanadaBoost Price TargetOutperform$27.00 ➝ $35.00Low
i
6/12/2020JPMorgan Chase & Co.Reiterated RatingOverweightLow
i
6/11/2020BarclaysReiterated RatingOverweightLow
i
6/11/2020SunTrust BanksBoost Price TargetBuy$36.00 ➝ $39.00Medium
i
6/11/2020HC WainwrightBoost Price TargetBuy$34.00 ➝ $40.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
6/3/2020BarclaysReiterated RatingOverweightMedium
i
6/3/2020Bryan, Garnier & CoDowngradeBuy ➝ NeutralLow
i
6/2/2020SunTrust BanksBoost Price TargetBuy$30.00 ➝ $36.00Low
i
6/2/2020DanskeDowngradeBuy ➝ HoldLow
i
6/1/2020HC WainwrightReiterated RatingPositive ➝ Buy$29.00 ➝ $34.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
5/26/2020UBS GroupUpgradeNeutral ➝ BuyLow
i
5/7/2020SunTrust BanksBoost Price TargetBuy$28.00 ➝ $30.00Low
i
5/7/2020HC WainwrightBoost Price TargetBuy$28.00 ➝ $29.00Low
i
Rating by Ram Selvaraju at HC Wainwright
5/1/2020HC WainwrightReiterated RatingBuy$28.00High
i
Rating by Ram Selvaraju at HC Wainwright
4/23/2020Credit Suisse GroupInitiated CoverageOutperformLow
i
4/15/2020Morgan StanleyLower Price TargetOverweight$31.00 ➝ $30.00Low
i
4/15/2020HC WainwrightLower Price TargetBuy$29.00 ➝ $28.00Low
i
Rating by Ram Selvaraju at HC Wainwright
4/6/2020Royal Bank of CanadaReiterated RatingBuy$27.00Medium
i
3/4/2020HC WainwrightReiterated RatingBuy$29.00Low
i
Rating by Ram Selvaraju at HC Wainwright
2/24/2020HC WainwrightReiterated RatingBuy$25.00 ➝ $29.00Low
i
Rating by Ram Selvaraju at HC Wainwright
2/20/2020Morgan StanleyBoost Price TargetOverweight$30.00 ➝ $31.00Medium
i
2/11/2020HC WainwrightReiterated RatingBuy$25.00Medium
i
Rating by Ram Selvaraju at HC Wainwright
1/22/2020HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
1/13/2020SunTrust BanksInitiated CoverageBuyMedium
i
12/12/2019Deutsche Bank AktiengesellschaftDowngradeBuy ➝ HoldHigh
i
12/11/2019HC WainwrightReiterated RatingBuy$25.00High
i
Rating by Ram Selvaraju at HC Wainwright
12/4/2019HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
11/20/2019HC WainwrightReiterated RatingBuy$25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
10/16/2019HC WainwrightBoost Price TargetBuy$24.00 ➝ $25.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/27/2019HC WainwrightSet Price TargetBuy$24.00Low
i
Rating by Ram Selvaraju at HC Wainwright
9/16/2019HC WainwrightReiterated RatingBuy$24.00Low
i
Rating by R. Selvaraju at HC Wainwright
9/13/2019Bank of AmericaUpgradeNeutral ➝ BuyMedium
i
9/12/2019JPMorgan Chase & Co.UpgradeNeutral ➝ Overweight$23.00Low
i
8/26/2019HC WainwrightReiterated RatingBuyLow
i
Rating by R. Selvaraju at HC Wainwright
8/12/2019GuggenheimInitiated CoverageBuy ➝ BuyMedium
i
8/12/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$23.00Low
i
8/12/2019Morgan StanleyInitiated CoverageOverweight ➝ OverweightLow
i
(Data available from 5/10/2016 forward)
Genmab A/S logo
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; ofatumumab, a human monoclonal antibody to treat chronic lymphocytic leukemia (CLL) and multiple sclerosis; and Arzerra for treating CLL. Its products under development include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; tisotumab vedotin for treating cervical, ovarian, and solid cancers; HuMax-IL8 for treating advanced cancers; HexaBody-DR5/DR5, DuoBody-CD3x5T4, JNJ-63898081, JNJ-70218902, DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; and DuoBody-CD3xCD20 and DuoHexaBody-CD37 for treating hematological malignancies. The company's products under development also comprise Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; HuMax-IL8 for treating advanced cancers; JNJ-61186372 for the treatment of non-small-cell lung cancer; JNJ-63709178 and JNJ-67571244 to treat acute myeloid leukemia; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating Parkinson's disease. In addition, it has approximately 20 active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with Immatics Biotechnologies GmbH to research and develop next-generation bispecific immunotherapies for treating multiple cancer indications; CureVac AG for the research and development of differentiated mRNA-based antibody products; AbbVie for the development of epcoritamab; and BioNTech, Janssen, Novo Nordisk A/S, and BliNK Biomedical SAS. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Read More

Today's Range

Now: $37.29
$37.24
$37.72

50 Day Range

MA: $34.52
$31.65
$37.28

52 Week Range

Now: $37.29
$27.24
$44.83

Volume

9,593 shs

Average Volume

588,571 shs

Market Capitalization

$24.46 billion

P/E Ratio

28.91

Dividend Yield

N/A

Beta

0.93

Frequently Asked Questions

What sell-side analysts currently cover shares of Genmab A/S?

The following Wall Street sell-side analysts have issued reports on Genmab A/S in the last year: Barclays PLC, Bryan, Garnier & Co, Credit Suisse Group AG, Danske, Deutsche Bank Aktiengesellschaft, DNB Markets, HC Wainwright, JPMorgan Chase & Co., Morgan Stanley, Royal Bank of Canada, Societe Generale, SunTrust Banks, Inc., SVB Leerink LLC, The Goldman Sachs Group, Inc., TheStreet, Truist, UBS Group AG, and Zacks Investment Research.
View the latest analyst ratings for GMAB.

What is the current price target for Genmab A/S?

7 Wall Street analysts have set twelve-month price targets for Genmab A/S in the last year. Their average twelve-month price target is $41.57, suggesting a possible upside of 11.5%. HC Wainwright has the highest price target set, predicting GMAB will reach $49.00 in the next twelve months. SVB Leerink LLC has the lowest price target set, forecasting a price of $36.00 for Genmab A/S in the next year.
View the latest price targets for GMAB.

What is the current consensus analyst rating for Genmab A/S?

Genmab A/S currently has 2 sell ratings, 4 hold ratings and 9 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in GMAB, but not buy more shares or sell existing shares.
View the latest ratings for GMAB.

What other companies compete with Genmab A/S?

How do I contact Genmab A/S's investor relations team?

Genmab A/S's physical mailing address is Kalvebod Brygge 43, Copenhagen G7, 1560. The company's listed phone number is 45-7020-2728 and its investor relations email address is [email protected] The official website for Genmab A/S is www.genmab.com.